⁃ General

• Ability to undergo 18F FLT imaging without sedation

• Patients \> 4 years of age and less than 80 years of age at highest risk for graft failure: cord blood HSCT, haplo HSCT, or lack of engraftment by day 28.

• Diagnosed with a condition for which hematopoietic stem cell transplant (HSCT) is standard of care and HSCT is planned (Arm A) or occurred (Arm B)

• In morphologic remission prior to HSCT

• Patient or guardian able to give informed consent

• Investigational therapies within past 28 days or planned on protocol are pre-approved by the PI or Site PI

• Karnofsky or Lansky performance status \> 60%

⁃ Arm A

• A1 Cord blood recipients: Absence of donor specific antibodies to cord HLA

• Haplo-identical recipients: ≥ 5/10 and \< 7/8 allele mismatch donor

• A2- myeloablative Haplo-identical transplant is planned

• A3- reduced intensity Haplo-identical transplant is planned (non-myeloablative is excluded)

• A1- myeloablative or reduced intensity transplant is planned (non-myeloablative is excluded)

• Diagnosed with a condition for which hematopoietic stem cell transplant (HSCT) is standard of care and HSCT is planned

• Total bilirubin \< 2.5 mg/dL (unless documented Gilbert's syndrome) and transaminases (ALT and AST) \< 5 x the upper limit of normal

• Creatinine clearance or GFR \> 60 ml/min/1.73 m2. (performed pre-HSCT)

• FEV1 \> 80% pre or post-bronchiolator whichever is higher and DLCO Adj \> 70% (performed pre-HSCT if age appropriate) and Sa02 \> 94% on room air

• Ejection fraction \> 50% (performed pre-HSCT)

⁃ Arm B

⁃ • Non-engraftment recipients of HCT with any donor source (related or unrelated): primary graft failure as defined by ANC not \> 500 for 3 consecutive days and at least 20 days after HSCT.

• 1-2 cords and \>.4/6 match to recipient for each (as per current National Marrow Donor guidelines), with a dose \>2 x 10e6 CD34 cells/kg for each cord OR \> 5/10 and \<7/8 allele mismatch related donor

• Institutional guidelines met for donor suitability